We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
DIAGNOSTIC ANTIBODY ASSAY
BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE
USE OF REGULATOR OF CALCINEURIN 1 FOR MANUFACTURING MEDICAMENT FOR TREATMENT OF DISEASES ASSOCIATED WITH INCREASED NF- B ACTIVITY
RADIOLABELLED GLUTAMINYL CYCLASE INHIBITORS
A METHOD OF ANTIBODY PURIFICATION
INHALATION SUPPORT APPARATUS AND METHOD FOR INHALATION SUPPORT
AN EXPRESSION VECTOR COMPRISING A POLYNUCLEOTIDE ENCODING A MODIFIED GLUTAMINE SYNTHETASE AND A METHOD FOR PREPARING A TARGET PROTEIN EMPLOYING THE SAME
Method for adapting decorative prints and device for carrying out said method
Thiourea derivatives as glutaminyl cyclase inhibitors
NOVEL MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO DLL4 AND USE THEREOF
New mineral binder and the use thereof for the manufacturing of wood-based panels
New fusion gene as therapeutic target in proliferative diseases
CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE
CRYSTAL STRUCTURE OF ISOGLUTAMINYL CYCLASE